Advertisement

A Flow Cytometry-Based Assay for the Evaluation of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in Cancer Cells

  • Nohemí Salinas-Jazmín
  • Emiliano Hisaki-Itaya
  • Marco A. Velasco-VelázquezEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1165)

Abstract

The development of new therapeutic monoclonal antibodies (mAbs) for cancer therapy will rise in the following years. The evaluation of biological activity of mAbs is required during drug development and during drug production as quality control test. Antibody-dependent cell-mediated cytotoxicity (ADCC) is a desirable activity of anticancer mAbs. Here, we describe a flow cytometry-based method to quantify ADCC that combines the staining of cancer cells, effector cells, and dead cells, with specific dyes. This method is inexpensive, has low background, and avoids the use of radioisotopes.

Key words

ADCC Flow cytometry Trastuzumab 7-AAD Biosimilar 

Notes

Acknowledgments

We thank Dr. Frank Robledo-Avila and Dra. Mayra Pérez-Tapia for the critical review of this manuscript. Assays presented in this work were performed at “Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI), Instituto Politécnico Nacional.” The work is supported by a grant from “Instituto Científico Pfizer, México” and grants IN219613 (PAPIIT-UNAM) and 225313 (Conacyt) to MAV-V.

References

  1. 1.
    Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287PubMedCrossRefGoogle Scholar
  2. 2.
    Adler MJ, Dimitrov DS (2012) Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 26:447–481, viiPubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Harrison A, Liu Z, Makweche S et al (2012) Methods to measure the binding of therapeutic monoclonal antibodies to the human Fc receptor FcgammaRIII (CD16) using real time kinetic analysis and flow cytometry. J Pharm Biomed Anal 63:23–28PubMedCrossRefGoogle Scholar
  4. 4.
    Levy EM, Roberti MP, Mordoh J (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011:676198PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Derby E, Reddy V, Kopp W et al (2001) Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunol Lett 78:35–39PubMedCrossRefGoogle Scholar
  6. 6.
    Collins DM, O'Donovan N, McGowan PM et al (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23:1788–1795PubMedCrossRefGoogle Scholar
  7. 7.
    Yeo C, Saunders N, Locca D et al (2009) Ficoll-Paque versus Lymphoprep: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen Med 4:689–696PubMedCrossRefGoogle Scholar
  8. 8.
    Pollara J, Hart L, Brewer F et al (2011) High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79:603–612PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Green MR, Kennell AS, Larche MJ et al (2005) Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 141:165–173PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Nohemí Salinas-Jazmín
    • 1
  • Emiliano Hisaki-Itaya
    • 1
  • Marco A. Velasco-Velázquez
    • 2
    Email author
  1. 1.Unidad de Desarrollo e Investigación en Bioprocesos (UDIBI)Escuela Nacional de Ciencias BiológicasMéxicoMéxico
  2. 2.Departamento de Farmacología, Facultad de MedicinaUNAMMéxicoMéxico

Personalised recommendations